|
1.
|
|
6 p, 870.5 KB |
Characterization of a cohort of metastatic lung cancer patients harboring KRAS mutations treated with immunotherapy : differences according to KRAS G12C vs. non-G12C
/
Notario, Lucía (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Cucurull, Marc (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Cerdà, Gabriela (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Sanz, Carolina (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Carcereny, Enric (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Muñoz-Mármol, Ana (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Hernández, Ainhoa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Domènech, Marta (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Morán, Teresa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Sanchez-Cespedes, Montse (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Costa, Marta (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Mate, Jose Luis (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Esteve, Anna (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Saigí, Maria (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Approximately 20% of lung adenocarcinomas harbor activating mutations at KRAS, an oncogene with the ability to alter the tumor immune microenvironment. In this retrospective study, we examined 103 patients with KRAS-mutant lung adenocarcinoma who were treated with immunotherapy-based regimens and we evaluated the clinical outcomes according to PD-L1 expression and the type of KRAS mutation. [...]
2023 -  10.3389/fonc.2023.1239000
Frontiers in Oncology, Vol. 13 (october 2023)
|
|
|
2.
|
|
|
Correlation of MR-Based Metabolomics and Molecular Profiling in the Tumor Microenvironment of Temozolomide-Treated Orthotopic GL261 Glioblastoma in Mice
/
Zhao, Kai (Philipps University Marburg) ;
Calero-Perez, Pilar (Institut d'Investigació Biomèdica Sant Pau) ;
Bopp, Miriam H.A. (Center for Mind. Brain and Behavior (CMBB)) ;
Möschl, Vincent (Philipps University Marburg) ;
Pagenstecher, Axel (Philipps-University Marburg) ;
Mulero-Acevedo, Marta (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ;
Vázquez, Mario (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ;
Barcia, Carlos (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ;
Arús i Caraltó, Carles (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ;
Nimsky, Christopher (Center for Mind. Brain and Behavior (CMBB)) ;
Rusch, Tillmann (Philipps University Marburg) ;
Bartsch, Joerg Walter. (Center for Mind. Brain and Behavior (CMBB)) ;
Candiota Silveira, Ana Paula (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular)
The tumor microenvironment in glioblastoma (GB) is considered to be "cold", i. e. , the fraction of cytotoxic T cells, for instance, is low. Instead, macrophages are the major immune cell population in GB, which stem either from tissue response (resident microglia) or recruitment of macrophages from the periphery, thereby undergoing tumor-dependent "imprinting" mechanisms by which macrophages can adapt a tumor-supportive phenotype. [...]
2023 - 10.3390/ijms242417628
International journal of molecular sciences, Vol. 24 Núm. 24 (december 2023) , p. 17628
|
|
|
3.
|
|
|
4.
|
|
9 p, 1.9 MB |
Effect of Sirolimus Exposure on the Need for Preemptive Antiviral Therapy for Cytomeglovirus Infection after Allogeneic Hematopoietic Stem Cell Transplantation
/
Guglieri-Lopez, Beatriz (Hospital Universitari Doctor Peset (València)) ;
Perez-Pitarch, Alejandro (Hospital Clínico Universitario de València) ;
Garcia Cadenas, Irene (Institut d'Investigació Biomèdica Sant Pau) ;
Gimenez, Estela (Hospital Clínico Universitario de València) ;
Barba, Pere (Hospital Universitari Vall d'Hebron) ;
Rabella, Núria (Institut d'Investigació Biomèdica Sant Pau) ;
Hernandez-Boluda, Juan Carlos (Hospital Clínico Universitario de València) ;
Fox, Maria Laura (Hospital Universitari Vall d'Hebron) ;
Valcárcel, David (Hospital Universitari Vall d'Hebron) ;
Esquirol, Albert (Institut d'Investigació Biomèdica Sant Pau) ;
Ferriols-Lisart, Rafael (Hospital Clínico Universitario de València) ;
Sierra, Jorge (Institut d'Investigació Biomèdica Sant Pau) ;
Solano, Carlos (Universitat de València) ;
Navarro, David (Universitat de València) ;
Martino Bofarull, Rodrigo (Institut d'Investigació Biomèdica Sant Pau) ;
Piñana, José Luis (Instituto de Salud Carlos III) ;
Universitat Autònoma de Barcelona
The current study evaluates the clinical effect of sirolimus exposure on the occurrence of cytomegalovirus (CMV)DNAemia necessitating preemptive antiviral therapy. A total of 167 consecutive recipients of reduced-intensity conditioning (RIC)allogeneic hematopoietic stem cell transplantation (allo-HSCT)who received sirolimus- and tacrolimus-based graft-versus-host disease (GVHD)prophylaxis and whose CMV serostatus was positive for donors and/or recipients were included in this multicenter retrospective study. [...]
2019 - 10.1016/j.bbmt.2019.01.012
Biology of blood and marrow transplantation, Vol. 25 Núm. 5 (may 2019) , p. 1022-1030
|
|
|
5.
|
|
12 p, 843.6 KB |
Association of hepatitis B virus infection status with outcomes of non-small cell lung cancer patients undergoing anti-PD-1/PD-L1 therapy
/
Zhang, Xuanye (Sun Yat-sen University Cancer Center) ;
Tian, Dan (Guangdong Academy of Medical Sciences) ;
Chen, Yue (The Eighth Affiliated Hospital of Sun Yat-sen University) ;
Chen, Chen (Sun Yat-sen University Cancer Center) ;
He, Li-Na (Sun Yat-sen University Cancer Center) ;
Zhou, Yixin (Sun Yat-sen University Cancer Center) ;
Li, Haifeng (Sun Yat-sen University Cancer Center) ;
Lin, Zuan (Sun Yat-sen University Cancer Center) ;
Chen, Tao (Sun Yat-sen University Cancer Center) ;
Wang, Yuhong (Sun Yat-sen University Cancer Center) ;
Russo, Alessandro (A.O. Papardo) ;
Nadal, Ernest (Hospital Universitari de Bellvitge) ;
Passiglia, Francesco (S. Luigi Gonzaga Hospital) ;
Soo, Ross Andrew (National University Health System) ;
Watanabe, Satoshi (Niigata University Graduate School of Medical and Dental Sciences) ;
Morán, Teresa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Oh, In-Jae (Hwasun Hospital) ;
Fu, Sha (Sun Yat-sen University) ;
Hong, Shaodong (Sun Yat-sen University Cancer Center) ;
Zhang, Li (Sun Yat-sen University Cancer Center) ;
Universitat Autònoma de Barcelona
The aim of this study was to evaluate the safety and survival outcomes of anti-programmed cell death (PD)-1/programmed cell death-ligand 1 (PD-L1) monotherapy in patients with advanced non-small cell lung cancer (NSCLC) and different hepatitis B virus (HBV) infection status. [...]
2021 - 10.21037/tlcr-21-455
Translational Lung Cancer Research, Vol. 10 (july 2021) , p. 3191-3202
|
|
|
6.
|
|
13 p, 6.8 MB |
CD69-oxLDL ligand engagement induces Programmed Cell Death 1 (PD-1) expression in human CD4 + T lymphocytes
/
Jiménez-Fernández, María (Centro de Investigación Biomédica en Red en Enfermedades Cardiovasculares) ;
Rodríguez, Cristina (Institut d'Investigació Biomèdica Sant Pau) ;
Cañes Esteve, Laia (Centro de Investigación Biomédica en Red en Enfermedades Cardiovasculares) ;
Ballester-Servera, Carme (Institut d'Investigació Biomèdica Sant Pau) ;
Vara, Alicia (Instituto de Investigación Hospital Universitario de la Princesa) ;
Requena, Silvia (Instituto de Investigación Hospital Universitario de la Princesa) ;
de la Fuente, Hortensia (Centro de Investigación Biomédica en Red en Enfermedades Cardiovasculares) ;
Martínez-González, José (Institut d'Investigació Biomèdica Sant Pau) ;
Sánchez-Madrid, Francisco (Centro de Investigación Biomédica en Red en Enfermedades Cardiovasculares)
The mechanisms that control the inflammatory-immune response play a key role in tissue remodelling in cardiovascular diseases. T cell activation receptor CD69 binds to oxidized low-density lipoprotein (oxLDL), inducing the expression of anti-inflammatory NR4A nuclear receptors and modulating inflammation in atherosclerosis. [...]
2022 - 10.1007/s00018-022-04481-1
Cellular and Molecular Life Sciences, Vol. 79 Núm. 8 (august 2022) , p. 468
|
|
|
7.
|
|
9 p, 884.2 KB |
Comparison of Ceftolozane/Tazobactam Infusion Regimens in a Hollow-Fiber Infection Model against Extensively Drug-Resistant Isolates
/
Montero, María Milagro (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Domene-Ochoa, Sandra (Institut Hospital del Mar d'Investigacions Mèdiques) ;
López-Causapé, Carla ;
López Montesinos, Inmaculada (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Luque, Sonia (Hospital del Mar (Barcelona, Catalunya)) ;
Sorlí, Luisa (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Campillo, Núria (Hospital del Mar (Barcelona, Catalunya)) ;
Padilla León, Eduardo ;
Prim, Núria ;
Ferrer Alapont, Lorena (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Grau, Santiago (Hospital del Mar (Barcelona, Catalunya)) ;
Oliver, Antonio ;
Horcajada, Juan Pablo (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Universitat Autònoma de Barcelona
The aim of this study was to compare the efficacy of intermittent (1-h), extended (4-h), and continuous ceftolozane-tazobactam (C/T) infusion against three extensively drug-resistant (XDR) sequence type (ST) 175 isolates with different susceptibilities to C/T (MIC = 2 to 16 mg/L) in a 7-day hollow-fiber infection model (HFIM). [...]
2022 - 10.1128/spectrum.00892-22
Microbiology Spectrum, Vol. 10 (june 2022)
|
|
|
8.
|
|
11 p, 3.4 MB |
PIVOT-12 : a phase III study of adjuvant bempegaldesleukin plus nivolumab in resected stage III/IV melanoma at high risk for recurrence
/
Eggermont, Alexander M. (Princess Máxima Center for Pediatric Oncology & University Medical Center Utrecht) ;
Ascierto, Paolo A. (Istituto Nazionale Tumori IRCCS Fondazione G Pascale) ;
Khushalani, Nikhil I. (H Lee Moffitt Cancer Center & Research Institute) ;
Schadendorf, Dirk (West German Cancer Center at the University Hospital Essen) ;
Boland, Genevieve (Massachusetts General Hospital (Boston)) ;
Weber, Jeffrey (Perlmutter Cancer Center at NYU Langone Health) ;
Lewis, Karl D. (University of Colorado Cancer Center) ;
Johnson, Daniel (Ochsner Medical Center) ;
Rivalland, Gareth (University of Auckland & Auckland City Hospital) ;
Khattak, Adnan (Hollywood Private Hospital. Edith Cowan University) ;
Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ;
Gogas, Helen (National & Kapodistrian University of Athens) ;
Long, Georgina V. (Melanoma Institute Australia. University of Sydney. Royal North Shore & Mater Hospitals) ;
Currie, Sue L. (Nektar Therapeutics, San Francisco, CA 94158, USA) ;
Chien, David (Nektar Therapeutics, San Francisco, CA 94158, USA) ;
Tagliaferri, Mary A. (Nektar Therapeutics, San Francisco, CA 94158, USA) ;
Carlino, Matteo S. (Westmead & Blacktown Hospitals & Melanoma Institute Australia. University of Sydney) ;
Diab, Adi (University of Texas MD Anderson Cancer Center)
Bempegaldesleukin (BEMPEG: NKTR-214) is an immunostimulatory IL-2 cytokine prodrug engineered to deliver a controlled, sustained and preferential IL-2 pathway signal. Nivolumab (NIVO), a PD-1 inhibitor, has been shown to prolong survival in patients with advanced melanoma and recurrence-free survival in the adjuvant setting. [...]
2022 - 10.2217/fon-2021-1286
Future oncology (London, England), Vol. 18 Núm. 8 (january 2022) , p. 903-913
|
|
|
9.
|
|
18 p, 1.7 MB |
Addition of Immune Checkpoint Inhibitors to Chemotherapy vs Chemotherapy Alone as First-Line Treatment in Extensive-Stage Small-Cell Lung Carcinoma : A Systematic Review and Meta-Analysis
/
Arriola, Edurne (Hospital del Mar (Barcelona, Catalunya)) ;
González-Cao, María (Hospital Dexeus) ;
Domine, Manuel (Hospital Universitario Fundación Jiménez Díaz) ;
de Castro, Javier (Hospital Universitario La Paz (Madrid)) ;
Cobo, Manuel (Instituto de Investigación Biomédica de Málaga) ;
Bernabé, Reyes (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Navarro, Alejandro (Vall d'Hebron Institut d'Oncologia) ;
Sullivan, Ivana (Institut d'Investigació Biomèdica Sant Pau) ;
Trigo, José Manuel (Hospital Universitario Virgen de la Victoria (Màlaga, Andalusia)) ;
Mosquera, Joaquín (Complejo Hospitalario Universitario de A Coruña) ;
Crama, Leonardo (Medical Department Roche) ;
Isla, Dolores (Hospital Clínico Universitario "Lozano Blesa" de Zaragoza)
Introduction: The addition of immune checkpoint inhibitors (ICIs) to conventional chemotherapy (CT) as first-line treatment improves survival in extensive-stage small-cell lung cancer (ES-SCLC). The aim of this meta-analysis was to determine the relative efficacy of first-line ICIs compared with CT in patients with ES-SCLC. [...]
2022 - 10.1007/s40487-021-00182-0
Oncology and Therapy, Vol. 10 Núm. 1 (june 2022) , p. 167-184
|
|
|
10.
|
|
13 p, 1.2 MB |
Association between Changes in the Patterns of Antinuclear Autoantibodies during Immune Checkpoint Inhibition Therapy and the Development of Severe Immune Related Adverse Events
/
Alserawan, Leticia (Institut d'Investigació Biomèdica Sant Pau) ;
Anguera, Georgia (Institut d'Investigació Biomèdica Sant Pau) ;
Zamora, Carlos (Institut d'Investigació Biomèdica Sant Pau) ;
Serra, Jorgina (Institut d'Investigació Biomèdica Sant Pau) ;
Martinez-Martinez, Laura (Institut d'Investigació Biomèdica Sant Pau) ;
Riudavets Melià, M. (Institut d'Investigació Biomèdica Sant Pau) ;
Sullivan, Ivana (Institut d'Investigació Biomèdica Sant Pau) ;
Barba Joaquin, Andrés (Institut d'Investigació Biomèdica Sant Pau) ;
Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ;
Vidal, Silvia (Institut d'Investigació Biomèdica Sant Pau)
Immune-related adverse events (irAEs) are unpredictable autoimmune-like toxicities induced by immune checkpoint inhibitors (ICI). irAEs are a consequence of a breakdown in self-tolerance. ICIs can induce autoantibody formation, and the presence of antinuclear autoantibodies (ANAs) has been reported in patients who developed irAEs. [...]
2022 - 10.3390/ijms232012641
International journal of molecular sciences, Vol. 23 Núm. 20 (october 2022) , p. 12641
|
|
visitant ::
identificació
alerta personal via correu electrònic o subscribiu-vos al 
canal RSS.
